Umeclidinium bromide
| |
Clinical data | |
---|---|
Trade names | Incruse Ellipta |
Synonyms | GSK573719A |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation (DPI) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | ~89%[1] |
Metabolism | Hepatic (CYP2D6) |
Elimination half-life | 11 hours |
Excretion | Feces (58%) and urine (22%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
KEGG | |
ChEBI | |
ECHA InfoCard |
100.166.375 |
Chemical and physical data | |
Formula | C29H34BrNO2 |
Molar mass | 508.49 g/mol |
3D model (JSmol) | |
| |
|
Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).[2][3]
External links
References
- 1 2 "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
- ↑ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
- ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.